Skip to Main content Skip to Navigation
Journal articles

Reversing endothelial dysfunction with empagliflozin to improve cardiomyocyte function in cardiorenal syndrome

Abstract : Sodium-glucose cotransporter 2 inhibitors offer cardiovascular and renal benefits in patients with chronic kidney disease through not yet clearly defined mechanisms. Juni et al. showed that sodium-glucose cotransporter 2 inhibitor empagliflozin exposure in vitro can restore cardiomyocyte function by counteracting harmful effects of uremic serum on the endothelium-cardiomyocyte crosstalk between endothelial cells and cardiomyocytes. The author's findings improved our understanding of cardiovascular impairment in chronic kidney disease and provided new perspectives for the beneficial effects of sodium-glucose cotransporter 2 inhibitor therapy.
Document type :
Journal articles
Complete list of metadata

https://hal.inrae.fr/hal-03256334
Contributor : Nelly Lucas <>
Submitted on : Thursday, June 10, 2021 - 11:09:48 AM
Last modification on : Friday, June 11, 2021 - 3:15:10 AM

Identifiers

Collections

Citation

Laetitia Dou, Stéphane Burtey. Reversing endothelial dysfunction with empagliflozin to improve cardiomyocyte function in cardiorenal syndrome. Kidney International, Nature Publishing Group, 2021, 99 (5), pp.1062-1064. ⟨10.1016/j.kint.2021.01.008⟩. ⟨hal-03256334⟩

Share

Metrics

Record views

4